Skip to main
WGS

WGS Stock Forecast & Price Target

WGS Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GeneDx Holdings is well-positioned to take advantage of the growing trend towards genomic testing, with a focus on pediatric and rare diseases. The company's plans to triple its sales force and expand into new markets, such as the pediatrician market and newborn screening, shows its commitment to growth and profitability. Although it may take time for these new opportunities to translate into revenue, GeneDx has a strong foundation and expertise in genomic testing, making it a promising investment for the future.

Bears say

GeneDx Holdings is facing several key risks, including hesitation from geneticists to fully adopt exome and genome testing, slow growth in the rare disease market and dependence on reimbursement decisions from clinicians. The recent quarter was disappointing, with revenue and gross margin missing expectations due to mix and softness in the non-core business. The company has lowered its guidance and our estimates for 2026-2028, and it will take time for its latest study results and expanded testing capabilities to potentially drive future growth and adoption in the market.

WGS has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GeneDx Holdings Corp (WGS) Forecast

Analysts have given WGS a Strong Buy based on their latest research and market trends.

According to 5 analysts, WGS has a Strong Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $75.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $75.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GeneDx Holdings Corp (WGS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.